EU regulator backs J&J COVID-19 booster dose for adults
Reuters
Published Dec 15, 2021 08:53AM ET
Updated Dec 15, 2021 01:47PM ET
(Reuters) - The European Union's drug regulator on Wednesday recommended that a booster dose of Johnson & Johnson (NYSE:JNJ)'s COVID-19 shot may be given at least two months after a first dose in people aged 18 years and older, as the bloc battles surging infections.
The Omicron coronavirus variant is swiftly spreading across the globe, with many new cases linked to the mutant and the World Health Organization warning that Omicron poses a "very high" risk but data on its severity is limited.
The European Medicines Agency (EMA) said its recommendation to allow J&J booster doses follows data which showed the additional shot led to a rise in antibodies against the COVID-causing SARS-CoV-2 coronavirus.
The EMA said that a J&J booster dose may also be given after two doses of one of the mRNA vaccines from Pfizer-BioNTech or Moderna (NASDAQ:MRNA), in line with its recommendation on mixing vaccines.
Several EU countries are tightening restrictions after at least one patient died in the United Kingdom after contracting the Omicron variant, which was first detected last month in southern Africa and Hong Kong.
The rolling out of booster doses is being stepped up as longevity of protection offered by standard vaccination has been under scrutiny due to Omicron, whose high number of mutations may enable it to escape protection offered by vaccines.
The EU watchdog has already endorsed vaccines from Pfizer-BioNTech and Moderna as a third booster dose at least six months after a standard two-shot course. It is also considering AstraZeneca (NASDAQ:AZN)'s booster doses.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.